Tri Locum Partners’s Tandem Diabetes Care TNDM Stock Holding History

Tri Locum Partners’s Portfolio TNDM Stock Details TNDM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-326,506	Closed	-$11.6M	–	34
2024 Q1	$11.6M	Buy	+326,506	New	+$8.75M	4.01%	12
2023 Q2	–	Sell	-417,448	Closed	-$17M	–	78
2023 Q1	$17M	Buy	+417,448	New	+$17.3M	5.16%	4

Other funds holding TNDM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Tri Locum Partners's TNDM Position: Q2 2024 in Review

Tri Locum Partners sold out of Tandem Diabetes Care (TNDM) in Q2 2024, closing a stake of 326,506 shares — an estimated $11.6M sold.

Tri Locum Partners first reported a position in TNDM in Q1 2023 and held it in 2 quarters. The position peaked at $17M in Q1 2023. 317 funds tracked by Wall St. Rank hold TNDM as of Q2 2024.

Tri Locum Partners reported no remaining Tandem Diabetes Care position as of Q2 2024 after selling out during the quarter.
Tri Locum Partners sold 326,506 Tandem Diabetes Care shares in Q2 2024, an estimated $11.6M.
Tri Locum Partners first reported a position in Tandem Diabetes Care in Q1 2023 and held it in 2 quarters.
Tri Locum Partners's Tandem Diabetes Care position peaked at $17M in Q1 2023.
317 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q2 2024.

Based on Tri Locum Partners's 13F filing for Q2 2024, filed 14 Aug 2024.